SVB Leerink

Celyad Oncology Announces Closing of $32.5 Million Private Placement with Fortress Investment Group Affiliate

Retrieved on: 
Wednesday, December 8, 2021
Slate, U.S. Securities and Exchange Commission, Risk, Fortress Investment Group, Wallonia, Company, Forward-looking statement, Research, GLOBE, Prospectus, SEC, Securities Act of 1933, CAR, Mont-Saint-Guibert, SA, Private Securities Litigation Reform Act, EUR, American depositary receipt, Lymphatic system, USD, Cancer, Skadden, Euronext, Uncertainty, Harvest, Intrinsic termination, RNA, Sale, Annual report, Fortification, SVB Leerink, Vaccine, Security (finance)

MONT-SAINT-GUIBERT, Belgium, Dec. 08, 2021 (GLOBE NEWSWIRE) -- Celyad Oncology SA (Euronext & Nasdaq: CYAD) (Celyad or the Company), a clinical-stage biotechnology company focused on the discovery and development of chimeric antigen receptor T cell (CAR T) therapies for cancer, today announced the closing of its previously announced private placement with an affiliate of Fortress Investment Group (such affiliate Fortress).

Key Points: 
  • MONT-SAINT-GUIBERT, Belgium, Dec. 08, 2021 (GLOBE NEWSWIRE) -- Celyad Oncology SA (Euronext & Nasdaq: CYAD) (Celyad or the Company), a clinical-stage biotechnology company focused on the discovery and development of chimeric antigen receptor T cell (CAR T) therapies for cancer, today announced the closing of its previously announced private placement with an affiliate of Fortress Investment Group (such affiliate Fortress).
  • The Company issued 6,500,000 ordinary shares at a price of USD 5.00 (about EUR 4.42) for gross proceeds of USD 32.5 million (about EUR 28.7 million).
  • SVB Leerink acted as the exclusive placement agent for the private placement, Goodwin Procter LLP and Harvest acted as legal counsel to the Company.
  • The Company has agreed to customary registration rights covering the resale of the ordinary shares (in the form of American Depositary Shares) sold in the private placement.

SVB Financial Group's Expansion into Tech Investment Banking Continues with New Senior Bankers and the Launch of Technology Leveraged Finance and Equity Capital Markets

Retrieved on: 
Monday, December 6, 2021
MAKE, Senior, Enterprise software, Merrill (company), Equity capital markets, UBS, Moody's Investors Service, HNA Technology Investments Holdings, Silicon, E-commerce, M&A, Blackstone, Initial public offering, Internet, CEO, Marketing, Hearst Communications, TPG Capital, SVB, Sale, Silicon Valley, JPMorgan Chase, Credit Suisse, Barclays, Deepening, Investment banking, Silicon Valley Bank, Growth, Valley Bank, Consumer, Acquisition, Jefferies, Chevron, Goldman Sachs, SSA Global Technologies, Cinven, SVB Leerink, Consumers Software, Software, SIVB, NASDAQ, Telecom, Mischler Financial Group, Brillstein Entertainment Partners, Financial services

SVB serves the world's most innovative companies and their investors via commercial banking with Silicon Valley Bank, investment banking with SVB Leerink, private banking and wealth management with SVB Private Bank, and funds management and investment with SVB Capital.

Key Points: 
  • SVB serves the world's most innovative companies and their investors via commercial banking with Silicon Valley Bank, investment banking with SVB Leerink, private banking and wealth management with SVB Private Bank, and funds management and investment with SVB Capital.
  • In September 2021 SVB announced the expansion of SVB Leerink to include technology investment banking.
  • Mattjoinsthe firm fromCredit Suisse where he was Managing Director and Co-Head of Global Technology, Media & Telecom Equity Capital Markets.
  • Raymond has advised on over 50 transactions with technology companies and financial sponsors including M&A, debt financing, and equity capital markets transactions.

Celyad Oncology Announces $32.5 Million Private Placement with Fortress Investment Group

Retrieved on: 
Friday, December 3, 2021
Slate, Fortification, Private Securities Litigation Reform Act, CAR, Sale, CEO, LLP, Securities Act of 1933, Technology, American depositary receipt, Lymphatic system, Annual report, Forward-looking statement, Company, Cancer, USD, SEC, SA, Euronext, Skadden, Intellectual property, Prospectus, Intrinsic termination, Fortress Investment Group, EUR, Research, Risk, SVB Leerink, Harvest, LLC, GLOBE, Wallonia, Association, RNA, U.S. Securities and Exchange Commission, Uncertainty, Mont-Saint-Guibert, Growth, IP, Vaccine, 3D printing, Security (finance)

Filippo Petti, CEO of Celyad Oncology, commented, This transformative investment provides an important springboard for the Company and further strengthens our corporate initiatives to advance our novel allogeneic CAR T product candidates.

Key Points: 
  • Filippo Petti, CEO of Celyad Oncology, commented, This transformative investment provides an important springboard for the Company and further strengthens our corporate initiatives to advance our novel allogeneic CAR T product candidates.
  • Celyad Oncology offers a unique optionality around its technology and intellectual property, said Christopher LiPuma, Director at Fortress.
  • SVB Leerink acted as the exclusive placement agent for the private placement, Goodwin Procter LLP and Harvest acted as legal counsel to the Company.
  • Forward-looking statements include statements regarding: the anticipated closing of the private placement, the use of proceeds from the private placement and Celyad Oncologys cash runway.

Trinity Life Sciences Recapitalizes With Kohlberg & Company

Retrieved on: 
Tuesday, November 30, 2021
Professional Services, Health, Other Science, Finance, General Health, Science, Pharmaceutical, Patient, Kohlberg & Company, CEO, LLP, Technology, Industry, Company, Jefferies Group, Centerview Partners, Solution, List of life sciences, Eye, Research, Investment, SVB Leerink, LLC, Board, Kirkland & Ellis, Ropes & Gray, Partner, Multimedia, Growth, Quality of life, Fine chemical, Kohlberg & Company, Trinity Life Sciences, KOHLBERG & COMPANY, TRINITY LIFE SCIENCES

Trinity Life Sciences , a leader in global life sciences commercialization solutions, announced today the signing of a definitive agreement for a recapitalization transaction led by Kohlberg & Company , a leading private equity firm with more than 30 years of experience.

Key Points: 
  • Trinity Life Sciences , a leader in global life sciences commercialization solutions, announced today the signing of a definitive agreement for a recapitalization transaction led by Kohlberg & Company , a leading private equity firm with more than 30 years of experience.
  • View the full release here: https://www.businesswire.com/news/home/20211130005656/en/
    We are thrilled to partner with Kohlberg & Co. through our next chapter of growth as we continue to empower the life sciences industry to deliver life-changing therapies to patients, said David Fitzhenry, CEO, Trinity Life Sciences.
  • We are thrilled to partner with Kohlberg & Co. through our next chapter of growth as we continue to empower the life sciences industry to deliver life-changing therapies to patients, said David Fitzhenry , CEO, Trinity Life Sciences.
  • Trinity Life Sciences is a trusted strategic commercialization partner, providing evidence-based solutions for the life sciences.

SVB Private Bank Appoints Rohit Mehrotra as Head of Relationship Management

Retrieved on: 
Tuesday, November 30, 2021
Princeton University, Private banking, FDIC, SVB, BS, Industry, Health care, Silicon, Mehrotra, SIPC, Big Brothers Big Sisters, Private bank, Federal Reserve, MBA, Economics, SEC, FINRA, Solution, List of life sciences, Business, Tuck School of Business, McCarter, Silicon Valley Bank, Trust, Cornell University, Nasdaq, View, SVB Leerink, Central, McCarter Theatre, Structure of the Federal Reserve System, Dartmouth College, SIVB, Multimedia, Wine, Financial services

SANTA CLARA, Calif., Nov. 30, 2021 /PRNewswire/ -- SVB Private Bank , a leading provider of private banking, wealth management and trust services, today announced the appointment of Rohit Mehrotra as head of relationship management.

Key Points: 
  • SANTA CLARA, Calif., Nov. 30, 2021 /PRNewswire/ -- SVB Private Bank , a leading provider of private banking, wealth management and trust services, today announced the appointment of Rohit Mehrotra as head of relationship management.
  • SVB Private Bank is one of SVB Financial Group's four core businesses, along with Silicon Valley Bank, SVB Leerink and SVB Capital, and provides a full spectrum of wealth, trust and private banking services dedicated to helping clients simplify and strengthen their financial positions.
  • As head of relationship management, Mehrotra will lead a team of advisors nationally who deliver holistic wealth advice to clients in the innovation economy.
  • Mehrotra will report to John Longley, head of the Private Bank, Wealth, Trust and Wine group.

Clover Announces Closing of Public Offering of Class A Common Stock

Retrieved on: 
Tuesday, November 23, 2021
Sale, Common stock, Broadridge Financial Solutions, SEC, Telephone, Prospectus, Citigroup, GLOBE, SVB Leerink, Deutsche Bank, Health equity, Clover, Security (finance)

NASHVILLE, Tenn., Nov. 23, 2021 (GLOBE NEWSWIRE) -- Clover Health Investments, Corp. (Nasdaq: CLOV), (Clover Health), a technology company committed to improving health equity for seniors, today announced the closing on November 22, 2021, of its previously announced underwritten public offering of shares of its Class A Common Stock, resulting in approximately $300 million of gross proceeds.

Key Points: 
  • NASHVILLE, Tenn., Nov. 23, 2021 (GLOBE NEWSWIRE) -- Clover Health Investments, Corp. (Nasdaq: CLOV), (Clover Health), a technology company committed to improving health equity for seniors, today announced the closing on November 22, 2021, of its previously announced underwritten public offering of shares of its Class A Common Stock, resulting in approximately $300 million of gross proceeds.
  • In connection with the offering, Clover also granted the underwriters a 30-day option to purchase up to 7,826,086 additional shares of its Class A Common Stock at the public offering price, less the underwriting discounts and commissions.
  • Citigroup and Deutsche Bank Securities acted as joint book-running managers for the offering.
  • SVB Leerink and Canaccord Genuity LLC acted as book-runners for the offering.

Kamada Announces Strategic Transformational Transaction Positioning the Company as a Global Leader in the Plasma-Derived Hyperimmune Market Through the Acquisition of a Portfolio of Four FDA-Approved Commercial Products

Retrieved on: 
Monday, November 22, 2021
Lung, Pregnancy, Disease, Company, Woman, Recurrence, Kidney, SDF, Agmon, Immunoglobulin G, Commercialization, Immunity, GLOBE, Contract, Food, HIV, Liver, Heart, Pancreas, DLA Piper, Private Securities Litigation Reform Act, Business architecture, Bleeding, Bank Hapoalim, Food and Drug Administration, AAT, KMDA, TASE, Chickenpox, Coronavirus, Forward-looking statement, Platelet, Partnership, Post-exposure prophylaxis, HBV, Transplant, FDA, Person, Therapy, Growth, Patient, Innova (video game company), Liver transplantation, Industry, Acquisition, Immunodeficiency, Plasma, 6, COVID-19, Organ transplantation, SVB Leerink, EMA, Knowledge, Antibody, CDC, Hepatitis B virus, ITP, NASDAQ, Fine chemical, Financial services, Pharmaceutical industry, Vaccine

WinRhoSDF is also used for suppression of Rhesus (Rh) Isoimmunization during pregnancy and other obstetric conditions in non-sensitized, Rho(D)-negative women.

Key Points: 
  • WinRhoSDF is also used for suppression of Rhesus (Rh) Isoimmunization during pregnancy and other obstetric conditions in non-sensitized, Rho(D)-negative women.
  • "The acquisition of this FDA-approved commercial portfolio represents a critical strategic and synergistic transaction and growth driver for Kamada, said Amir London, Kamadas Chief Executive Officer.
  • To partially fund the acquisition costs, Kamada has secured a $40 million credit facility from Bank Hapoalim, Israels leading commercial bank.
  • Kamada Ltd. (the Company) is a global specialty plasma-derived biopharmaceutical company with a diverse portfolio of marketed products, a robust development pipeline and industry-leading manufacturing capabilities.

Privia Health Announces Pricing of Secondary Offering

Retrieved on: 
Friday, November 19, 2021
Patient, Security (finance), Health, Sale, Risk, Industry, Forward-looking statement, Company, Leadership, Goldman Sachs, U.S. Securities and Exchange Commission, Telephone, Prospectus, Nasdaq, Attention, Credit Suisse, SVB Leerink, GLOBE, LLC, J. P. Morgan

ARLINGTON, Va., Nov. 18, 2021 (GLOBE NEWSWIRE) -- Privia Health Group, Inc. (Nasdaq: PRVA, or Privia Health or the Company), a technology-driven, national physician enablement company that collaborates with medical groups, health plans and health systems, announced the pricing of its previously announced underwritten public offering of 6,000,000 shares of common stock by certain selling stockholders at a public offering price of $29.00 per share.

Key Points: 
  • ARLINGTON, Va., Nov. 18, 2021 (GLOBE NEWSWIRE) -- Privia Health Group, Inc. (Nasdaq: PRVA, or Privia Health or the Company), a technology-driven, national physician enablement company that collaborates with medical groups, health plans and health systems, announced the pricing of its previously announced underwritten public offering of 6,000,000 shares of common stock by certain selling stockholders at a public offering price of $29.00 per share.
  • The Company will not receive any of the proceeds from the secondary offering.
  • Privia Health is a technology-driven, national physician enablement company that collaborates with medical groups, health plans, and health systems to optimize physician practices, improve patient experiences, and reward doctors for delivering high-value care in both in-person and virtual settings.
  • Privia Health undertakes no obligation to update these statements for revisions or changes after the date of this press release, except as required by law.

Clover Health Investments, Corp. Announces Pricing of $300 Million Upsized Public Offering of Class A Common Stock

Retrieved on: 
Thursday, November 18, 2021
Security (finance), Sale, Chamath Palihapitiya, Securities Act of 1933, Risk, Common stock, Forward-looking statement, Broadridge Financial Solutions, SEC, U.S. Securities and Exchange Commission, Telephone, Prospectus, Citigroup, Securities Exchange Act of 1934, GLOBE, SVB Leerink, Deutsche Bank, Health equity, Life insurance

In addition, Clover Health has granted the underwriters a 30-day option to purchase up to 7,826,086 additional shares of its Class A Common Stock at the public offering price, less the underwriting discounts and commissions.

Key Points: 
  • In addition, Clover Health has granted the underwriters a 30-day option to purchase up to 7,826,086 additional shares of its Class A Common Stock at the public offering price, less the underwriting discounts and commissions.
  • The aggregate gross proceeds to Clover Health from the offering are expected to be approximately $300 million, before deducting underwriting discounts and commissions and offering expenses and assuming no exercise of the underwriters option to purchase additional shares.
  • Clover Health intends to use the net proceeds from this offering for working capital and general corporate purposes.
  • Clover Health assumes no obligation, and does not intend, to update these forward-looking statements as a result of future events or developments.

ANI Pharmaceuticals Completes Acquisition of Novitium Pharma, Significantly Enhancing R&D Capabilities and Scale of Generics and CDMO Businesses

Retrieved on: 
Monday, November 22, 2021
Biotechnology, Pharmaceutical, Health, Patient, Private Securities Litigation Reform Act, Senior, Security (finance), News, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, PIPE, Lalwani, Houlihan Lokey, Acquisition, Company, Achievement, EBITDA, Term loan, Hypertension, Mark (given name), Hart–Scott–Rodino Antitrust Improvements Act, SEC, Leadership, U.S. Securities and Exchange Commission, Food, Nature, COVID-19, Annual report, Melinda Haag, Physician, Food and Drug Administration, Nasdaq, R, Risk, ANI, SVB Leerink, Purchasing, Contract manufacturer, Anders (singer), Terminology, Development, Hughes Hubbard & Reed, FDA, Form 10-K, Gel, CGT, FTC, Contract, CDMO, Failure, Growth, Transaction, Pharmaceutical industry, Management, Bank

Today marks a major milestone for ANI and the many patients who rely on our high-quality, cost-effective medications.

Key Points: 
  • Today marks a major milestone for ANI and the many patients who rely on our high-quality, cost-effective medications.
  • We are energized by todays events and look forward to strong contributions in driving the future success of an united ANI.
  • Novitium has expanded the 505 (b)(2) portfolio beyond the three initial 505(b)(2) candidates in Oncology and Hypertension.
  • Additionally, Novitium brings a U.S. based, state-of-the-art manufacturing facility enhancing manufacturing capabilities and CDMO opportunities.